BlossomHill Therapeutics, Inc. - Common Stock (NQ:BLSM)

17.48 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	17.48
Bid (Size)	16.00 (1,000)
Ask (Size)	18.44 (100)
Prev. Close	17.48
Today's Range	17.48 - 17.48
52wk Range	15.25 - 27.99
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

September 28, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

September 18, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

Performance

52-Week Range 37.5% below 52-week high

17.48

15.2552W Low 27.9952W High

1 Week 13.1% below 1-week high

16.121W Low 20.111W High

BlossomHill Therapeutics, Inc. - Common Stock (BLSM) traded between $15.25 and $27.99 over the past 52 weeks and last traded at $17.48, 37.5% below its 52-week high. Over the past week it ranged between $16.12 and $20.11.

Past 12 Months

-12.3%

-16.2%

+9.3%

1W -$2.46

1M -$3.38

3M +$1.48

6M +$1.48

YTD +$1.48

1Y +$1.48

BLSM was +9.3% over the past year, +9.3% over six months, +9.3% year to date, -12.3% in the last week.

12 Months vs Market

BLSM

+9.3%

DIA

+12.0%

SPY

+17.4%

QQQ

+24.8%

IWM

+14.1%

Over the past 12 months BLSM returned +9.3% versus DIA (Dow) +12.0%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +24.8% and IWM (Russell 2000) +14.1%.

Volume & Liquidity

199.9K

243.8K

258.4K

YTD

258.4K

BLSM's 3-month average daily volume is 258.4K.

More News

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

September 15, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

September 03, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

September 01, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

Insiders Are Betting Big on These 3 Healthcare Stocks ↗

August 31, 2026

Via MarketBeat

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

August 18, 2026

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is BlossomHill Therapeutics, Inc. - Common Stock publicly traded?

Yes, BlossomHill Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does BlossomHill Therapeutics, Inc. - Common Stock trade on?

BlossomHill Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BlossomHill Therapeutics, Inc. - Common Stock?

The ticker symbol for BlossomHill Therapeutics, Inc. - Common Stock is BLSM on the Nasdaq Stock Market

What is the current price of BlossomHill Therapeutics, Inc. - Common Stock?

The current price of BlossomHill Therapeutics, Inc. - Common Stock is 17.48

When was BlossomHill Therapeutics, Inc. - Common Stock last traded?

The last trade of BlossomHill Therapeutics, Inc. - Common Stock was at 10/09/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.